Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elcubragistat (Primary)
  • Indications Gilles de la Tourette's syndrome; Tic disorders
  • Focus Therapeutic Use
  • Sponsors Abide Therapeutics

    • Most Recent Events

    • 30 Nov 2021 Results assessing the exploratory study to determine the effect of Lu AG06466 versus placebo on tics and other symptoms in patients with Tourette Syndrome, published in the Pharmacopsychiatry.
    • 10 Apr 2018 According to an Abide Therapeutics media release, data from this trial will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting 2018.
    • 02 Nov 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top